People with Lp(a) gene variant may benefit from daily aspirin – Harvard Health

For years, “Should I take a daily aspirin?” was the kind of question people asked the way they asked,
“Should I drink more water?” (Answer: probably, but also… it depends.) Then the research got awkward:
for many people who have never had a heart attack or stroke, daily aspirin can cause more harm than help,
mainly by increasing serious bleeding risk.

Now comes an interesting plot twist from Harvard Health: a specific Lp(a) genetic variantlinked to
higher levels of lipoprotein(a)may identify a group of people who could get more heart-protection benefit
from low-dose aspirin than the average person. In other words, the “aspirin math” might look different if your
genes load the dice toward clotting and artery trouble.

Let’s break down what Lp(a) is, why a gene variant matters, what “daily aspirin” actually does, and how to think
about testing and next stepswithout turning your breakfast into a pharmaceutical planning meeting.

Meet Lp(a): The Sneaky Cholesterol Cousin

What is lipoprotein(a), exactly?

Lipoprotein(a)written as Lp(a) (“LP little a”)is a particle in your blood that resembles LDL
(“bad cholesterol”), but with an extra protein attached called apolipoprotein(a). That extra piece is a big
deal: it makes Lp(a) more likely to contribute to plaque buildup, inflammation, and clotting. Think of LDL as
the box sliding toward your artery walland Lp(a) as the same box with a little “troublemaker” sticker on it.

Why Lp(a) feels unfair: it’s mostly genetic

Unlike LDL cholesterol, Lp(a) is largely determined by genetics. For many people, diet and exercise won’t move
the number much (even if they’re still excellent for overall heart health). Levels tend to remain fairly stable
over time, which is one reason many experts talk about measuring it at least onceespecially if you have a family
history of early heart disease.

Why it matters: heart attacks, strokes, and aortic valve stenosis

Elevated Lp(a) is associated with higher risk of atherosclerotic cardiovascular disease (ASCVD)like heart attacks
and ischemic strokesand it’s also linked to calcific aortic valve stenosis (a stiff, narrowed valve over time).
This is one reason Lp(a) has been getting more attention: it can help explain “mystery risk” when LDL looks okay
but heart disease shows up early in a family.

Why Daily Aspirin Fell Out of Fashion (for Many People)

Primary vs. secondary prevention: the most important distinction

Aspirin is well established for secondary preventionmeaning people who have already had a heart
attack, stroke, stent placement, or certain kinds of vascular disease may benefit because preventing another event
is a very high priority. In that context, the benefit often outweighs the risk.

For primary preventionpeople who have never had a cardiovascular eventthe story is more mixed.
Large studies found that aspirin’s clot-prevention benefits are often offset by higher rates of serious bleeding,
especially gastrointestinal bleeding and (more rarely) bleeding in the brain. That’s why several guidelines now
discourage routine daily aspirin for most people who haven’t had a prior event.

So what changed? Better prevention toolsand clearer bleeding risk

Over time, we got better at preventing first-time heart events with tools that don’t raise bleeding risk as much:
controlling blood pressure, quitting smoking, treating diabetes, and using statins when appropriate. Meanwhile,
aspirin’s bleeding risk became harder to ignoreparticularly as people age or take other medications that can
irritate the stomach lining or affect clotting.

A quick guideline snapshot (plain English)

The Harvard Health Twist: A Gene Variant That May Change the Aspirin Equation

The idea: personalize aspirin using genetics

Harvard Health highlighted research suggesting that people with a genetic variant linked to higher Lp(a) levels
may see a stronger protective effect from low-dose aspirin than people without that variant. In the Harvard summary,
aspirin use in variant carriers was associated with a reduction in heart-attack-related outcomes that brought their
risk closer to people without the variant.

Why Lp(a) might respond differently to aspirin

Aspirin works mainly by reducing platelet “stickiness” (platelets help form clots). Elevated Lp(a) is thought to
contribute to cardiovascular risk not only through plaque and inflammation, but also through thrombosis-related
mechanismsbasically, making the blood more prone to clot in the wrong place at the wrong time. If your baseline
risk is more “clot-driven,” an antiplatelet like aspirin could have more upsideat least in theory and in some
study findings.

What is the “genetic aspirin test”?

The Harvard Health piece describes a commercially available test that looks for an Lp(a)-related genetic variant.
It’s typically presented as a one-time test (because your genes don’t change), and the basic pitch
is simple: if you have the variant, you may be more likely to be in a group where aspirin benefits outweigh risks.

Important reality check: a genetic signal is not a universal “YES, TAKE ASPIRIN” stamp. It’s a clue that helps
guide a risk-benefit conversationespecially because bleeding risk still matters.

Should You Get Tested for Lp(a) or the Variant?

Many clinicians start with an Lp(a) blood test (the particle level itself), because it directly
answers: “How high is your Lp(a)?” Genetics can help explain why, but the level tells you the current risk marker.
Some professional groups recommend measuring Lp(a) at least once in adulthood, and especially when personal or
family history suggests hidden risk.

People who often bring Lp(a) testing up with their clinician

• Family history of early heart attack, stroke, or sudden cardiac events
• Known familial hypercholesterolemia (FH) or very high LDL running in the family
• Personal history of premature ASCVD or significant plaque with “normal-ish” standard cholesterol numbers
• Aortic stenosis in the family, especially at younger-than-expected ages
• Trying to fine-tune risk assessment when decisions (like aspirin or statin intensity) feel borderline

Understanding results without spiraling

Labs may report Lp(a) in mg/dL or nmol/L. A commonly used “high” threshold is
around 50 mg/dL (or roughly 125 nmol/L), but many experts emphasize risk is a
continuum: higher is generally worse, and context matters. Also, you can’t reliably convert mg/dL to nmol/L with
a single magic multiplier because the particle size varies between people.

If Lp(a) Is High, What Actually Helps Right Now?

1) Get aggressive about the basics (yes, the “boring” stuff)

If Lp(a) is high, the usual risk factors matter even more. It’s like playing defense when the other team has a
star player: you tighten everything else.

• Lower LDL cholesterol to an appropriate target for your overall risk
• Control blood pressure (consistently, not “when you remember”)
• Don’t smoke (and avoid “social smoking,” which is still smoking)
• Manage diabetes/insulin resistance if present
• Prioritize sleep, movement, and a heart-healthy eating pattern

2) Medications: reducing risk even if Lp(a) doesn’t budge much

Statins are still a cornerstone for lowering LDL and reducing events. Some data suggest statins may not lower Lp(a)
and can even raise it slightly in some peoplebut the overall cardiovascular risk reduction from statins is strong,
so Lp(a) concerns generally aren’t a reason to avoid them when they’re indicated.

PCSK9 inhibitors can significantly lower LDL and often modestly lower Lp(a). For very high-risk patients with high
LDL and high Lp(a), they can be part of an “everything we’ve got” strategy.

3) Targeted Lp(a)-lowering therapies: promising, but still proving outcomes

Several therapies aimed specifically at lowering Lp(a) (including antisense and siRNA approaches) have shown large
reductions in Lp(a) levels in clinical studies. The key unanswered question is the one that really matters:
do these reductions translate into fewer heart attacks and strokes over time? Large outcomes trials are underway.
Until then, most care focuses on aggressive management of modifiable risk factors.

Where Aspirin Fits: A Smarter, More Personalized Conversation

If you’re considering aspirin for primary prevention, the goal is not to win an argument with the internetit’s to
win years of healthy life while avoiding preventable harm. That’s why the conversation should include:
overall cardiovascular risk, Lp(a) level/genetics, and bleeding risk.

Common factors that raise bleeding risk

• Prior gastrointestinal bleeding or ulcers
• Bleeding disorders or low platelet counts
• Use of anticoagulants (“blood thinners”) or certain other medications that increase bleeding risk
• Older age (risk rises as we age)
• Uncontrolled high blood pressure
• Heavy alcohol use

Especially important for teens and families

If you are under 18, do not start aspirin on your own. Aspirin is generally avoided in children and
teenagers with viral illnesses because of the rare but serious risk of Reye’s syndrome. Any aspirin
decision for minors should be made with a licensed clinician who knows the full medical picture.

A Practical Script: What to Ask Your Clinician

1. “Should I get an Lp(a) blood test based on my family history and other risk factors?”
2. “If my Lp(a) is elevated, how does that change my overall riskand my LDL goal?”
3. “Given my risk profile, would aspirin ever make sense for me, or does my bleeding risk make it a bad bet?”
4. “Is genetic testing for an Lp(a)-related variant useful in my case, or is the blood level enough?”
5. “What’s our plan: lifestyle targets, medication options, and follow-up timing?”

Quick FAQ (Because Everyone Googles at 1:00 a.m.)

Can I lower Lp(a) with diet and exercise?

Lifestyle changes are fantastic for blood pressure, triglycerides, insulin resistance, inflammation, and overall risk.
But Lp(a) itself is usually stubborn because it’s largely genetic. Don’t think “lifestyle doesn’t matter.” Think
“lifestyle matters even more, because Lp(a) is hard to change.”

Is the gene variant the same as having high Lp(a)?

Not exactly. A variant can increase the likelihood of elevated Lp(a), but the simplest practical step is often
measuring the Lp(a) level directly. Genetics may help with personalization (like the aspirin question), but clinicians
typically interpret everything in the full context of risk.

If aspirin can help, why not just take it and hope for the best?

Because bleeding risk is realand preventable. The best-case scenario is fewer clots; the worst-case scenario is a
serious bleed that lands you in the hospital. The “right” answer is the one where benefit clearly outweighs harm for
you, not the average person in a brochure.

Conclusion: The Future of Prevention Looks More Like “You” and Less Like “Everyone”

The Harvard Health update points to something heart medicine is steadily learning: the era of one-size-fits-all prevention
is fading. Lp(a)especially when driven by certain genetic variantsmay identify people whose cardiovascular risk is high
enough that aspirin’s protective effect becomes more meaningful.

Still, aspirin is not a DIY vitamin. If Lp(a) is on your radar, the smartest move is to pair that information with a
clinician-guided plan: optimize LDL and other risk factors, consider whether Lp(a) testing (and possibly genetics) helps
clarify your risk, and only then weigh aspirin using a clear-eyed benefit-versus-bleeding discussion.

Bonus: Real-World Experiences with Lp(a) and the “Aspirin Question” (About )

When people first learn they have elevated Lp(a) or an Lp(a)-related genetic variant, the most common reaction is a mix
of confusion and mild outrage. Confusion because it’s not always part of a standard cholesterol paneland outrage because
the number often doesn’t budge no matter how many salads someone heroically eats. Many describe it as discovering a “hidden
difficulty setting” for heart risk: they were doing the right things, yet their family history (or a surprise test result)
suggests the playing field wasn’t level.

A typical experience goes like this: someone gets routine labs, everything looks decent, but a parent or sibling has a heart
event “too young.” Their clinician orders Lp(a), and suddenly there’s an explanation that fits the family story. That moment
can be oddly relievingbecause it replaces vague anxiety with a concrete targetbut also frustrating, because the target is
harder to treat than LDL. People often say, “So I can’t outrun this?” The better framing is, “You can’t erase it today, but
you can absolutely manage the rest of the risk aggressively.”

Then comes the aspirin conversation. Many patients remember older relatives taking a daily aspirin for decades, so they assume
it’s a harmless preventive rituallike flossing, but chalkier. In clinic, they learn that for primary prevention, aspirin is
a trade-off: potential protection from clot-related events versus a real possibility of gastrointestinal bleeding, easy bruising,
or anemia over time. That’s where the Lp(a) gene-variant angle feels empowering: instead of “aspirin is good” or “aspirin is bad,”
it becomes “aspirin might be good for this subset of people.”

People also describe the family ripple effect. Because Lp(a) is strongly genetic, one elevated result can lead to siblings,
parents, and even adult children getting tested. Some families turn it into a supportive (and slightly chaotic) group project:
comparing results, trading cardiology appointment tips, and realizing that prevention is a team sport. Others find it emotionally
complicatedespecially if a relative had an early heart event and no one knew Lp(a) existed. The helpful takeaway is that testing
isn’t about blame; it’s about giving the family better information going forward.

Another common experience is the “what can I control?” reset. People often double down on controllables: keeping LDL lower than
they previously aimed for, taking blood pressure seriously, lifting weights consistently, walking more, improving sleep, and being
more intentional with nutrition. The emotional shift matters: instead of feeling stuck with a genetic number, they build a prevention
plan around risk reduction that is proven to help. Some even report that once they had a planregular follow-ups, clear targets, and a
clinician who took Lp(a) seriouslythe anxiety eased because uncertainty was replaced by action.

Finally, a lot of people discover that “personalized prevention” means personalized patience. They keep an eye on emerging Lp(a)-lowering
therapies, but they don’t wait passively. They treat today’s risk factors like they matterbecause they doand use new research (like the
Harvard Health aspirin-genetics insight) as a prompt to ask better questions, not to self-prescribe. In the best cases, that approach turns a
scary lab result into a clearer, calmer long-term strategy.

SEO Tags